Strategies for disease modification in Alzheimer's disease

  title={Strategies for disease modification in Alzheimer's disease},
  author={Martin O. Citron},
  journal={Nature Reviews Neuroscience},
  • M. Citron
  • Published 1 September 2004
  • Biology
  • Nature Reviews Neuroscience
Treating Alzheimer's disease (AD) is the biggest unmet medical need in neurology. Current drugs improve symptoms, but do not have profound disease-modifying effects. Three main classes of disease-modification approaches can be defined: one that is broadly neurotrophic or neuroprotective, one that targets specific aspects of AD pathology, and one that is based on epidemiological observation. This review discusses all three approaches, with particular emphasis on anti-amyloid strategies… 
Therapeutic approaches to Alzheimer's disease.
Currently available drugs as well as novel therapeutic strategies, in particular those targeting amyloid and tau pathologies, are discussed.
Emerging therapeutics for Alzheimer’s disease
The key pathological events in the AD brain are deposition of insoluble amyloid-β peptide, formation of neurofibrillary tangles and neuroinflammation leading, ultimately, to neuronal cell death.
Molecular Pathogenesis and Interventional Strategies for Alzheimer's Disease: Promises and Pitfalls.
Different disease modification approaches are discussed and the novel therapeutic targets of AD are addressed that might pave the way for new drug discovery using the well-defined targets for therapy of the disease.
Clinical Trials of Amyloid-Based Therapies for Alzheimer's Disease
  • P. Tariot
  • Biology, Psychology
    CNS Spectrums
  • 2007
Non-traditional dementia therapies such as the HMG-CoA reductase inhibitors (statins), valproate, and lithium are now being assessed for clinical benefit as anti-amyloid disease-modifying treatments.
Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application
  • C. Pietrzik, C. Behl
  • Biology, Psychology
    International journal of experimental pathology
  • 2005
Some of clinically applied treatment options are presented, which may improve AD symptoms for a short period but so far lack the ability to prevent or halt this devastating disease.
Current perspectives on pharmacotherapy of Alzheimer's disease
An overview of a wide array of therapeutic approaches under investigation, and the perspectives developed in the last 10 years, suggests that in the not-too-distant future, a synergistic combination of agents will have the capacity to alter the neurodegenerative cascade and reduce the global impact of this devastating disease.
Alzheimer's disease, estrogens, and clinical trials: a case study in drug development for complex disorders
On balance, estrogens remain a fruitful drug development approach for AD, and other neurodegenerative conditions, and especially those estrogen compounds or analogues that avoid or minimize the complications associated with long‐term use of feminizing hormones in post‐menopausal women.
Current pharmacotherapy for Alzheimer's disease.
As knowledge of the mechanisms responsible for neurodegeneration in AD increases, it is anticipated that neuroprotective drugs to slow or prevent neuronal dysfunction and death will be developed to complement current symptomatic treatments.


The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
It has been more than 10 years since it was first proposed that the neurodegeneration in Alzheimer's disease (AD) may be caused by deposition of amyloid β-peptide in plaques in brain tissue and the rest of the disease process is proposed to result from an imbalance between Aβ production and Aβ clearance.
Cholesterol and the Biology of Alzheimer's Disease
Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge.
  • M. Citron
  • Biology
    Trends in pharmacological sciences
  • 2004
Therapeutic standards in Alzheimer disease.
  • R. Doody
  • Medicine, Psychology
    Alzheimer disease and associated disorders
  • 1999
One large-scale clinical trial suggests that Vitamin E has sufficient benefit and safety to join donepezil as a current standard of AD therapy.
Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease
Estimation of the overall chance of individuals exposed to arthritis or anti-inflammatory drugs developing AD as compared with the general population and population-based studies with rheumatoid arthritis and NSAID use as risk factors suggest anti- inflammatory drugs may have a protective effect against AD.
Evaluation of memantine for the treatment of Alzheimer’s disease
  • S. Ferris
  • Biology, Psychology
    Expert opinion on pharmacotherapy
  • 2003
Increasing evidence suggests that disturbances in glutamatergic activity play an important role in Alzheimer’s disease (AD). Excessive glutamate-mediated activation of NMDA receptors, for example,
Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease
Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss
This article verifies the predicted accumulation of soluble oligomers in AD frontal cortex and confirms the prediction that soluble oligomeric Aβ ligands are intrinsic to AD pathology, and validate their use in new approaches to therapeutic AD drugs and vaccines.
Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease
Data show that chronic NSAID treatment can reduce brain Aβ levels, amyloid plaque burden, and microglial activation in an animal model of Alzheimer's disease.